Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Oxford Biodynamics Plc | OBD | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.2075 | 09:36:55 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.2075 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 22/10/2024 12:13 by tomboyb I'm afraid it does not change the medium term outlook -OBD requires cash - |
Posted at 22/10/2024 12:02 by tomboyb Logo Description automatically generatedOxford BioDynamics ("OBD" or the "Company" and, together with its subsidiaries, the "Group") EpiSwitch® CiRT Receives Clinical Approval from New York State Clinical Laboratory Evaluation Program (NYS CLEP) Oxford, UK - 22 October 2024 - Oxford BioDynamics, Plc (AIM: OBD, the Company), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on OBD's EpiSwitch® 3D genomics platform, and its partner NEXT Molecular Analytics (VA, USA) have been informed of New York State Clinical Laboratory Evaluation Program's (NYS CLEP) approval of the EpiSwitch® CiRT Test. "This is a significant milestone for any laboratory-developed test (LDT), including the CiRT test, and for the EpiSwitch platform." stated Thomas Guiel, Chief Operating Officer, "NYS CLEP is a rigorous program which bears similarities to the FDA premarket review process1. Both programs seek to mitigate the risks of harm from inaccurate and potentially unreliable LDTs. In the FDA's final ruling on LDTs earlier this year, they stated that they would not enforce their premarket review process for LDTs approved by NYS CLEP." "NYS CLEP provides an independent review of the analytical and clinical validity of any test. OBD and NEXT Molecular have been notified that the CiRT Test has passed this evaluation and been approved for clinical use." The FDA News release of 29 April 20241 states: "The FDA has also included additional enforcement discretion policies, such as for LDTs approved by the New York State's Clinical Laboratory Evaluation Program (CLEP), as described in the preamble to the final rule, where that program's review of analytical and clinical validity helps to mitigate the risk of harm from inaccurate and unreliable LDTs." 1 - FDA News Release, FDA Takes Action Aimed at Helping to Ensure the Safety and Effectiveness of Laboratory Developed Tests | FDA -Ends- |
Posted at 18/10/2024 21:33 by elpirata seriously, what is the point of obd paying for this other than to try sucking in gullible punters, quite disgraceful never mind embarrassingWe initiate with a valuation of £162m or 52p per share We value Oxford BioDynamics using a three-phase DCF based on peak future testing volumes. We initiate coverage with a valuation of £162/$203m, equivalent to 52p per share FY25e includes £20m of cash inflows included as illustrative short-term debt. |
Posted at 14/10/2024 12:12 by smithie6 will the many rampers for OBD on the main msg board now take a step forward & apologise for talking absolute rubbish for the last 3-6 months ?---- And the company's claim of having a super accurate test for prostate cancer imo that has been shown to be complete rubbish almost no one bought the product !! & a working real product would have a very long queue of buyers at the door. |
Posted at 14/10/2024 06:14 by tomboyb I'm afraid OBD is just the tip as we can see across the board -Companies are beginning to fall off like flies - |
Posted at 14/10/2024 06:08 by tomboyb Logo Description automatically generatedOxford BioDynamics ("OBD" or the "Company" and, together with its subsidiaries, the "Group") Commercial update on financial year ended 30 September 2024 Growth in test sales over the year, new sales model initiated and resources focused on PSE. Business restructured to maximise runway, with a material reduction in costs. Oxford, UK - 14 October 2024 - Oxford BioDynamics, Plc (AIM: OBD, the Company), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on OBD's EpiSwitch® 3D genomics platform today issues a commercial update following its financial year ended 30 September 2024. The Company has also commenced steps to reduce the cost base and maximise the cash runway through a comprehensive review of the strategic options open to the Company. EpiSwitch® CiRT CiRT orders in the second half of the financial year were 25% increased on the first half. The final financial quarter ended with 95 tests for September, bringing the total number of tests ordered since launch to 1,266. A total of 671 tests were ordered in the financial year. Following the launch of the PROWES Registry Study - a prospective observational study - at up to 12 sites across the US, with up to 2,500 patients to expedite the inclusion of CiRT into the National Comprehensive Cancer Network (NCCN) Guidelines - three regional study sites have been onboarded to date. CiRT tests carried out in the study are being run on normal commercial terms through our CLIA-accredited labs. By the end of August, it was evident that the majority of CiRT orders were now coming through the PROWES initiative and that the CiRT test would need to be included in NCCN Guidelines before we could expect significant traction from oncologists. Consequently, the Company has been able to reallocate its field sales resources to growing orders for the PSE test, without increasing the cost base. In the next financial year, the main focus of the Group's CiRT team will be on completion of patient enrolment into PROWES, alongside continuing to support those oncologists already using the test in their day-to-day practice. The Group will also shortly begin running CiRT tests on blood samples from patients enrolled in a clinical trial of an immune checkpoint inhibitor in endometrial cancer, for a top 10 pharma company. EpiSwitch® PSE PSE has grown steadily with orders in the second half of the year increased by 86% to 483 tests (H1: 259 tests) and more than 90 tests ordered in each month in the last quarter to the end of September. Total tests ordered since launch to the end of the financial year were 747. The recent redeployment of sales resources from the CiRT vertical to the PSE vertical has increased the number of salespersons dedicated to PSE five-fold, without increasing costs. Retraining of sales staff began in the first week of September, with the expanded and newly focused PSE sales team deployed in the field in the first week of October. Compared to CiRT, PSE has a much lower barrier to entry, because it already fits the American Urological Association (AUA)/NCCN guideline definition for prostate cancer screening. The expanded team, led by Dr Steve Arrivo, will focus on building on the traction gained so far for PSE in the concierge medicine space. Concierge practitioners are entrepreneurial, focused on patient outcomes and able to embrace innovation. Sales to such clinics are typically on a cash-pay basis. There are approximately 2,000 concierge clinics in the US which converts to an addressable market for this segment of circa 150,000 cash-pay tests per annum. In addition, we have been reimbursed for PSE tests under our existing CPT/PLA code (0433U) by several US insurers including Humana, UHC, Medicare and Optum Health. In the UK, sales of the test have come through the Company's partnership with the Goodbody Clinic and from private clinics such as The London Clinic. PSE has received a high level of attention within the industry because of its accuracy and ease of use. This has led to ongoing discussions with two of the leading diagnostic services companies in the US for a distribution deal that would widen access to the test and have the potential to add significant volume. Strategy and funding The Board acknowledges that access to capital in the UK market is limited and the burn rate of the Company has been high in order to get to its current position. In this context, the Board and management recognises the need to maximise the Company's cash runway, both in the short and longer term, and is initiating a series of cost-saving actions that will materially reduce the business's monthly cash cost base, whilst maintaining support for both CiRT and PSE as set out above. The management team remains wholly confident in the inherent value of the Company's test products and its EpiSwitch platform and therefore, as part of these plans, directors, PDMRs and certain other senior staff have agreed to take 25% of their net pay in newly issued shares for the foreseeable future. Chief Executive Officer, Dr Jon Burrows will take 35% of his net pay in newly issued shares. Notwithstanding the measures being taken to reduce the cost base, the Company will require additional cash resources by early Q1 of 2025. The Board has therefore launched a comprehensive review of the strategic options open to the Company. In addition to exploring available funding options, the review will consider a range of potential actions, including but not limited to a licensing or sale of Company assets - such as the EpiSwitch NST and EpiSwitch SCB tests - and a possible hive-off of the Company's US business into a separately funded entity. Currently, the strategic review does not envisage an offer for the Company under the City Code of Takeovers and Mergers. A further announcement regarding the outcome of the review will be provided in due course. The Company expects to publish preliminary results for the year ended 30 September 2024 in January 2025, following the financial audit. A further commercial update on the first quarter of the 2025 financial year will be provided at that time. -Ends- For more information: |
Posted at 17/7/2024 20:18 by pj84 It looks like the MRC meeting dates might have been on 3 and 4 July.If so, 10 working days from 4 July would be 18 July and if successful OBD should be notified tomorrow with possibly an RNS tomorrow or the day after. |
Posted at 22/6/2024 19:39 by npk2 I'll remember to ask your permission to post my thoughts on a free thread before I post next time.I wasn't aware that you were the monitor for discussion on OBD. |
Posted at 21/6/2024 23:00 by pj84 Obviously it's a free bet and the worst that can happen for the CEO is that the bet lapses without ever being exercised.But with 10m share options it clearly incentives the CEO. If he doubles the share price from the fund raise to 18p he stands to benefit by nearly £1m. Not sure why you have chosen OBD to share your wisdom on, as as far as I can see, the last 10 pages (could be more) of your posting history seems to be solely on the "Flat Earth" thread and the "New World order" thread, neither of which appear to be investment threads? But each to there own. |
Posted at 18/6/2024 21:56 by pj84 There are significant risks and so far I have taken a small position in OBD, particularly as the potential for the PSE test is huge.There is no guarantee the rate of increase in tests will grow as quickly as I hope, but I hope it does and that could lead to an increase in share price and the potential for raising at a higher price and I will be interested to see the update in early October. However, if you listened to the webinar update today you will have heard that for both the PSE and CiRT tests OBD isn't stubbornly going to try and avoid partnerships with big companies with deep pockets and big distribution networks and they are prepared to explore partnerships that could have an upfront payment, with milestone payments and royalties and the CEO said that a lower upfront payment tied to milestone payments to tie in with the interests of a partner would be attractive looking at the growing royalties on the market penetration a big partner could open up. I hope that is what they manage to do. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
